The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index; 25 of the 49 sources its claims cite were checked for support.
Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial
Open accessAbstract
Abstract Aims Approximately two-thirds of obesity-related mortality is attributable to cardiovascular disease (CVD). The aim of this analysis is to examine predicted CVD risk reduction following weight loss in persons with obesity for primary prevention between tirzepatide and semaglutide, and projected CVD events that could be potentially prevented in the USA. Methods and results SURMOUNT-5 was a Phase 3b, open-label, randomized trial conducted in participants with obesity and without Type-2 diabetes, comparing tirzepatide (10 or 15 mg) with semaglutide (1.7 or 2.4 mg) and administered via weekly subcutaneous injection. Predicted 10-year CVD risks were compared between treatments at baseline and up to 72 weeks post-treatment among participants without prior CVD. The impact of cardiovascular risk reduction was estimated as the projected preventable CVD events over 10 years for tirzepatide and semaglutide in the USA. The average predicted 10-year CVD risk score before treatment was 9.3%. Treatment with tirzepatide was associated with significantly greater reduction in predicted 10-year CVD risk compared with semaglutide (absolute reduction from baseline of 2.4% and 1.4%, respectively, P < 0.001). Translating risk reduction to the US population who met treatment eligibility criteria and without prior CVD (∼85 million), an estimated 2 million CVD events could be potentially prevented over 10 years after 72 weeks of tirzepatide treatment, vs. 1.15 million with semaglutide. Conclusion In SURMOUNT-5, treatment with tirzepatide was associated with greater predicted 10-year CVD risk reduction compared with semaglutide. This post hoc analysis suggests tirzepatide treatment may provide greater benefit in primary prevention of CVD than semaglutide in people with obesity and overweight. Registration ClinicalTrials.gov: NCT05822830
Overview
CoChat Summary
## TL;DR
In this post hoc analysis of SURMOUNT-5, tirzepatide was associated with a larger predicted 10-year CVD risk reduction than semaglutide in adults with obesity or overweight without diabetes or prior CVD. The modeled benefit translated to an estimated 2.0 million preventable CVD events over 10 years with tirzepatide vs 1.15 million with semaglutide in an eligible U.S. population.
## Key findings
- Among 576 participants without pre-existing CVD who completed 72 weeks, mean baseline predicted 10-year CVD risk was 9.3%.
- At 72 weeks, the absolute reduction in predicted 10-year CVD risk was 2.36% with tirzepatide vs 1.35% with semaglutide, with P < 0.001.
- Relative reduction from baseline was 23.72% with tirzepatide vs 13.56% with semaglutide (P < 0.001); the marginal HR was estimated as 0.87.
- In the U.S. treatment-eligible population without prior CVD (about 85 million), the model projected 2.0 million CVD events potentially prevented over 10 years with tirzepatide vs 1.15 million with semaglutide.
## Methods
- Post hoc analysis of the phase 3b, multicentre, open-label, randomized, active-controlled SURMOUNT-5 trial comparing weekly subcutaneous tirzepatide (10 or 15 mg) with semaglutide (1.7 or 2.4 mg) for 72 weeks.
- Analysis used patient-level data from participants without baseline CVD events; 576 participants who completed treatment were included in the per-protocol, complete-case analysis.
- Predicted 10-year CVD risk was calculated using Framingham-based BMI-specific sex-specific equations, and treatment differences were tested with ANCOVA adjusting for baseline risk score, prediabetes status, BMI group, sex, and age; subgroup analyses examined sex, race, and BMI group.
- U.S. population impact was projected using NHANES 2021–23 sample-weighted estimates of treatment-eligible adults without diabetes or prior CVD.
## Limitations
- The paper states that the Framingham risk equations were developed in a predominantly White population; although sensitivity analyses with the AHA PREVENT formula were directionally consistent, the authors note that more racially diverse data are needed.
- The “prevented events” estimate was a scenario-based projection rather than an observed outcome.
- The semaglutide dose mix in SURMOUNT-5 included both 1.7 mg and 2.4 mg, and the authors note this may limit generalizability to settings where only 2.4 mg is an approved maintenance dose.
- Smoking status was only collected at baseline, so the study may underestimate overall CVD risk reduction if some participants quit smoking during follow-up.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
17 Valid · 1 Not valid · 13 Not checked · 30 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“The SELECT trial, which included 17 604 participants over 45 years old with established CVD, a BMI of 27 kg/m2 or higher and without T2D, demonstrated that semaglutide reduced three-point major adverse cardiovascular events by 20% compared with placebo over a mean follow-up duration of 39.8 months.27”
§ Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial > Discussion
What the sources say
- Supportedcites [27] Lincoff, 2023, Semaglutide and cardiovascular outcomes in obesity without diabetes, N Engl J Med source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The predicted 10-year CVD risk score was calculated using the BMI-based sex-specific risk equations (supplementary material online, Methods), which were developed from the Framingham Heart Study by D’Agostino et al.15”
§ Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial > Methods > Cardiovascular disease risk score calculation
What the sources say
- Supportedcites [15] D’Agostino, 2008, General cardiovascular risk profile for use in primary care: the Framingham Heart Study, Circulation source
The section on simpler CVD risk prediction models says the authors developed sex-specific models using body mass index and other office-based predictors. The paper describes these as Framingham-derived CVD risk functions and reports 10-year risk estimates. This supports the citation as identifying the equations used; it does not independently verify the citing study's calculation. (LLM, conf=0.92)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“While studies have reported beneficial effects in cardiovascular outcomes in populations with T2D,19–23 data to understand the long-term health benefits, such as CVD risk reduction, in patients with obesity are limited.24,25”
§ Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial > Discussion
What the sources say
- Supportedcites [24] Nanna, 2025, Population-level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: a modelling study based on the SELECT trial, Diabetes Obes Metab source
The Discussion (page unavailable) says that semaglutide’s cardiovascular benefit has not been studied for as long as 10 years and that its projected benefit over that period is uncertain. It also notes that other obesity therapies are still being studied for cardiovascular outcomes. Together, these passages support the statement that data on long-term CVD risk reduction in patients with obesity are limited. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [25] Lusk, 2024, Cardiovascular event reduction among a US population eligible for semaglutide per the SELECT trial, Am Heart J source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Nevertheless, there has not been a head-to-head comparison for meaningful CV event rates between the two agents in a single trial in high-risk populations.13,14”
§ Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial > Introduction
What the sources say
- Supportedcites [13] Wong, 2024, US population eligibility and estimated impact of tirzepatide treatment on obesity prevalence and cardiovascular disease events, Cardiovasc Drugs Ther source
The Discussion reports cardiovascular outcome results for semaglutide from SELECT but says there were no actual cardiovascular event data for tirzepatide because its outcomes trial was still ongoing. That supports the absence of a single trial directly comparing event rates for the two agents; the paper does not use the phrase “head-to-head.” Page numbers were not provided in our copy. (LLM, conf=0.88)
- Partly supportedcites [14] Wong, 2025, US population eligibility and estimated impact of semaglutide treatment on obesity prevalence and cardiovascular disease events, Cardiovasc Drugs Ther sourceExperimental — accuracy not yet measured
In the Discussion (no page numbering in our copy) the paper presents the semaglutide and tirzepatide evidence only as separate, non-comparative trials — STEP 1 risk-factor changes for semaglutide versus SURMOUNT-1 for tirzepatide — and states that the 'ongoing SELECT trial will inform how semaglutide therapy and its associated risk factor changes translates into cardiovascular outcomes in adults with obesity and established CV disease and without diabetes,' which supports the claim's underlying point that cardiovascular-event data in high-risk obesity populations were not yet available and no comparison of the two agents is reported. However, our copy nowhere asserts that no head-to-head trial exists, says nothing about tirzepatide cardiovascular outcomes data (SURMOUNT-1 is cited only for weight and lipid/BP changes), and does not use the framing of 'meaningful cardiovascular event rates' or a head-to-head design, so that specific part of the attributed claim is not stated. Searches for 'head-to-head comparison tirzepatide semaglutide', 'cardiovascular outcomes not yet available', and 'SELECT trial high-risk' returned only these risk-factor/Ongoing-SELECT passages and reference-list entries. (LLM, conf=0.62)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The estimated baseline 10-year CVD risk in the SURMOUNT-5 data is slightly lower than in the work by Wong et al., due to the lower proportion of males (34% and 50%, respectively) and a younger population (mean age 44.8 and 47.3, respectively).”
§ Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial > Discussion
What the sources say
- Supportedcites [13] Wong, 2024, US population eligibility and estimated impact of tirzepatide treatment on obesity prevalence and cardiovascular disease events, Cardiovasc Drugs Ther source
The Results report a mean age of 47.3 years and a baseline 10-year CVD risk of 10.14% in Wong et al.’s NHANES sample. Table 2 shows males account for 41.7 million of the 84.1 million people represented, approximately 50%. The Discussion says that the sample’s older age and higher proportion of men would raise baseline CVD risk; the comparison with SURMOUNT-5 is the citing authors’ inference. (LLM, conf=0.88)
- Supportedcites [14] Wong, 2025, US population eligibility and estimated impact of semaglutide treatment on obesity prevalence and cardiovascular disease events, Cardiovasc Drugs Ther source
Wong et al.'s Table 1 (Results) gives the NHANES STEP-1-eligible sample as age 47.3 ± 0.5 years with female sex 50.6% (i.e. ~49-50% male; weighted 46.0 M of 93.0 M in Table 3), matching the '50% male' and 'mean age 47.3' figures the citing sentence attributes to this work. The estimated baseline (pre-treatment) 10-year CVD risk is likewise in our copy: 10.15% overall by the BMI-based Framingham equation in the 3,493 (82.8 M) participants without prior CVD (Results, 'Changes in CVD 10-year Risk and Preventable CVD Events'; Table 4), with 7.62% in the laboratory-based sensitivity analysis. The comparison with SURMOUNT-5 and the causal attribution of the difference to sex composition and age are the citing authors' own inference, not a statement taken from Wong et al.; everything attributed to this source is present in it. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
28 more claims · 4 with their cited sources checked
Create a free account to see all 61 claims and to verify the 5 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
- The quote only partly states this claim. 1
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491 · cited 3×
“The predicted 10-year CVD risk score was calculated using the BMI-based sex-specific risk equations (supplementary material online, Methods ), which were developed from the Framingham Heart Study by D’Agostino et al. 15 The general CVD events predicted in the model included coronary heart disease, stroke, peripheral a…”
InfluentialOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 1×
“9,11 The results are consistent between these current analyses of SURMOUNT-5 data and those by Wong et al. 13,14 particularly in the treatment effect of tirzepatide vs. semaglutide on CVD risk reduction.”
Obesity and cardiovascular disease: a scientific statement from the American Heart Association
Powell-Wiley, T. M., Poirier, P., Burke, L. E., Després, J.-P., Gordon-Larsen, P., Lavie, C. J., Lear, S. A., Ndumele, C. E., Neeland, I. J., Sanders, P., et al. (2021) · Circulation · doi:10.1161/cir.0000000000000973 · Cited by 3,691
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208 · cited 3×
“38 Excess adiposity/obesity acts as both an initiating factor and an amplifier of metabolic dysfunction, promoting insulin resistance, systemic inflammation, and dyslipidaemia—all of which contribute to CVD and CKD. Cardiovascular-kidney-metabolic syndrome carries serious clinical consequences,…”
InfluentialSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 2×
“This study used the latest NHANES survey of 2021–23 to identify participants that met the study criteria (see Supplementary material online, Table S1 ) and used sample weighting to generalize to the US population in millions.”
Development and validation of the American Heart Association’s PREVENT equations
Khan, S. S., Matsushita, K., Sang, Y., Ballew, S. H., Grams, M. E., Surapaneni, A., Blaha, M. J., Carson, A. P., Chang, A. R., Ciemins, E., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067626 · Cited by 1,234
Khan, S. S., Ning, H., Wilkins, J. T., Allen, N., Carnethon, M., Berry, J. D., Sweis, R. N., & Lloyd-Jones, D. M. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.0022 · Cited by 1,072
Research works printed but not linked: 2
- CDC, 2021–2023, National Health and Nutrition Examination Survey (NHANES) Data
- Waters, 2018, America’s Obesity Crisis. The Health and Economic Costs of Excess Weight
Cited by
Pratley, R. E., Denham, D. S., Trivedi, R., Watkins, E., Connery, L., Barnes, J., Yu, D., Hong, J., Simard, C., Umans, K., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04440-4 · Cited by 26
Cardiovascular Prevention: Current Gaps and Future Directions
Dores, H., Santos, J. F., Gil, V. M., & Gonçalves, P. D. A. (2025) · Diagnostics · doi:10.3390/diagnostics16010016 · Cited by 18
Abdul‐Hafez, H. A., Awashra, A., Bdir, S., Saife, S., Salah, Q., Barbarawi, M., Swaileh, T., Emara, A., Elgendy, M. S., & Shubietah, A. R. M. (2026) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70152 · Cited by 9
The Global Obesity Epidemic: Epidemiology, Health Burden and Policy Priorities
Henney, A. E., & Wilding, J. P. H. (2026) · European Cardiology Review · doi:10.15420/ecr.2025.84 · Cited by 4
Do, D., Murugiah, K., Sawano, M., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2025.102575 · Cited by 2
Metadata
- Authors
- Mamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H.
- Affiliations
- Keele University (GB)
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Eli Lilly (United States) (US)
- Eli Lilly and Company , 307 E Merrill, Indianapolis, IN 46285 ,
- Venue
- European Heart Journal Open
- Publisher
- Oxford University Press (OUP)
- Published
- 2025-08-29
- Volume
- 5
- Issue
- 5
- Pages
- oeaf117-oeaf117
- ISSN
- 2752-4191 (ISSN-L)
- PMC
- PMC12448458
- OpenAlex
- W4413939100
- Cited by
- 24
- References
- 35
- Citations by year
- 2026: 21 · 2025: 3
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- European Heart Journal Open (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- tirzepatide, semaglutide, obesity, cardiovascular risk, primary prevention, weight loss, overweight, GLP-1 receptor agonists, GIP/GLP-1 dual agonist
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. https://app.cochat.ai/papers/10.1093/ehjopen/oeaf117
- The paper
- Mamas, M. A., Bays, H., Li, R., Upadhyay, N., Irani, T., Senyucel, C., Dunn, J. P., & Liu-Seifert, H. (2025). Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction in obesity: post-hoc analysis of the SURMOUNT-5 trial. European Heart Journal Open. https://doi.org/10.1093/ehjopen/oeaf117
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.